Collectionner le produit
Détails du produit
Synonyms
TNFRSF4, OX40, CD134, OX40L receptor, ACT35, TXGP1L
Source
Canine OX40 Protein, Fc Tag (OX0-C5253) is expressed from human 293 cells (HEK293). It contains AA Glu 29 - Gln 215 (Accession # XP_038520220.1).
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 47.2 kDa. The protein migrates as 55-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.1 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Canine OX40 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Canine OX40 Protein, Fc Tag (Cat. No. OX0-C5253) is more than 90% and the molecular weight of this protein is around 95-125 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Canine OX40 Ligand Protein, His Tag (Cat. No. OXL-C5244) at 5 μg/mL (100 μL/well) can bind Canine OX40 Protein, Fc Tag (Cat. No. OX0-C5253) with a linear range of 0.1-4 ng/mL (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Tumor necrosis factor receptor superfamily member 4
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
29 Détails
- Étape de développement la plus élevée：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
